JG
NTLA icon

Joel Greenblatt’s Intellia Therapeutics NTLA Stock Holding History

Joel Greenblatt’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,290
Closed -$451K – 1054
2020
Q4 		$451K Buy
+8,290
New +$301K 0.01% 729

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Joel Greenblatt's NTLA Position: Q1 2021 in Review

Joel Greenblatt sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 8,290 shares — an estimated $451K sold.

Joel Greenblatt first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $451K in Q4 2020. 261 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Joel Greenblatt reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Joel Greenblatt sold 8,290 Intellia Therapeutics shares in Q1 2021, an estimated $451K.
  • Joel Greenblatt first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Joel Greenblatt's Intellia Therapeutics position peaked at $451K in Q4 2020.
  • 261 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Gotham Asset Management's 13F filing for Q1 2021, filed 17 May 2021.